24d agoBusiness InsiderNEUTRAL 50General
HIMS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Hims & Hers Health, Inc.
NEW YORK CITY, NY / ACCESS Newswire / August 19, 2026 / ( ACCESS NEWSWIRE )-The law firm of
Archived explainer. For the current picture see today's HIMS page.
Why Is HIMS & HERS HEALTH I A (HIMS) Stock Up Today?
By the Top Tier Newswire AI Desk · August 20, 2026 at 10:05 AM ET · reviewed against 13 wire stories
HIMS & HERS HEALTH I A (HIMS) is up +6.19% in the latest session. Our newswire has captured 13 stories on HIMS across 5 sources in the last 36 hours, with AI sentiment reading mixed (avg 50/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why HIMS stock is up today
HIMS stock rose 6.19% to $33.02 in morning trading on August 20, 2026. The move followed a gap down open of -1.8% and a sharp intraday reversal driven by a mix of investor sentiment and recent coverage. The stock reached a session high of $33.16 at 10:00 AM ET, suggesting a short-term rebound amid ongoing legal and regulatory scrutiny.
What Happened
The stock opened at $30.52 after closing at $31.09 the previous session. Despite a gap down, the price reversed sharply higher within the first two hours of trading. This upward movement came amid a flurry of legal and investor alerts. Over the past 36 hours, 13 stories from five different sources highlighted ongoing investigations and legal actions. These include a major FTC lawsuit over privacy and billing practices, as well as multiple law firm announcements investigating potential securities law violations. The company has rejected the privacy allegations and emphasized its commitment to expanding patient access. Meanwhile, Citigroup and Deutsche Bank updated their price targets, with Citigroup lowering its target to $33 and Deutsche Bank raising its target to $26.
What The Data Shows
The session saw 4.0 million shares traded, a volume that is 0.2 times the 3-month daily average. The stock’s price trend over the last 8 sessions had been negative, declining from $31.66 to $31.09. The current price of $33.02 is above the 52-week range high of $65.30, but remains within the broader context of a volatile year. The stock has a market cap of $6.4 billion and is unprofitable, with an EPS of -0.62 for the trailing twelve months. Recent insider transactions show 8 sell filings totaling $5.9 million and 1 buy totaling $1.2 million over the last 90 days. Unusual options activity included a notable put premium of $83,000, indicating bearish positioning.
What To Watch
The stock is set to continue under legal and regulatory scrutiny. Investors should monitor the ongoing FTC case and any new developments from the law firms investigating potential securities violations. Additionally, the company’s upcoming product launches and international expansion could influence future stock performance.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
HIMS by the numbers
Last: $33.02Session: +6.19%7 sessions: +2.82%Coverage: 13 stories / 5 sourcesAI sentiment: 50/100 (mixed)Mkt cap: $6.4B52w: $13.74 to $65.30
The headlines behind the move
24d agoPR NewswireBEARISH 34General
Hims & Hers Health (NYSE: HIMS) Stock Plunges 14% Following Major FTC Lawsuit Over Privacy & Billing; Hagens Berman Investigates Corporate Compliance and Investor Ramifications
SAN FRANCISCO, Aug. 19, 2026 /PRNewswire/ -- investors in Hims & Hers Health, Inc. (NYSE: HIMS) saw the price of their shares slide about 14% lower on news that the FTC sued the company over alleged improper business practices. The events have prompted national shareholders rights firm...
24d agoBusiness InsiderNEUTRAL 48General
Kaplan Fox is Investigating Hims & Hers Health, Inc. (HIMS) on Behalf of Investors for Potential Securities Law Violations
New York, New York--(Newsfile Corp. - August 19, 2026) - Kaplan Fox Kilsheimer LLP is investigating...
24d agoSeeking AlphaBULLISH 65Analyst
Hims & Hers: Buying The Margin Dip
Hims & Hers Health (HIMS) is rated a buy at current levels, driven by robust international expansion and product innovation.
25d agoThe Motley FoolNEUTRAL 50General
Hims & Hers' Chief Accounting Officer Is Leaving. Here's What Her Latest Insider Filing Shows
This filing notes that shares were withheld automatically to cover tax obligations from quarterly RSU vesting.
25d agoThe Motley FoolNEUTRAL 54General
An Insider at Hims & Hers Just Filed. Here's What It Says About Buying the Dip
Soleil Boughton retains roughly 339,000 shares and additional derivative securities.
25d agoThe Motley FoolNEUTRAL 50General
What Long-Term Investors Should Know About This Hims Insider Filing
This tax-related withholding was tied to quarterly RSU vesting, not discretionary selling.
25d agoThe Motley FoolNEUTRAL 48General
A Hims & Hers Insider Disposed of Stock as the Company Pushes Into Testosterone and Peptides. Here's What to Know
Tax withholding drove the disposal of 10,201 shares at $28.15 each, reducing this insider's direct holdings by 5%, though they're still up on a net basis given conversions.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on HIMS: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier HIMS move explainers: 2026-09-08 · 2026-08-28 · 2026-08-27 · 2026-08-26 · 2026-08-25 · 2026-08-24 · 2026-08-20 · 2026-08-19